Samantha Du, Ph.D. founded Zai lab in 2014 and has been its Director, CEO, and Chair of the Board since its inception. Prior to founding Zai Lab, Dr. Du spent two years at Sequoia Capital China where she led four healthcare investments and served on the boards. From 2001 to 2011, Dr. Du co-founded Hutchison MediPharma and Hutchison China MediTech and has been its Chief Executive Officer and Chief Scientific Officer, respectively, since their inceptions. Dr. Du began her research career with Pfizer in the United States from 1994 till 2001 after receiving her Ph.D. in biochemistry from the University of Cincinnati.
Billy Cho has been our Chief Financial Officer since March 2018. Prior to joining Zai Lab, Mr. Cho was the Managing Director and Head of Asia Healthcare Investment Banking at Citigroup. Based in Hong Kong since 2011, Mr. Cho was responsible for healthcare client coverage at Citigroup across the Asia Pacific region and led many important biopharma transactions in China including Zai Lab's US IPO. Prior to this, he was based in New York in healthcare M&A investment banking and also spent time in corporate development for a pharmaceutical services company. Mr. Cho started his career at Ernst & Young performing financial audits of US-based healthcare companies.
Mr. Cho earned his M.B.A. from the Wharton School of the University of Pennsylvania and M.A. in Accounting from University of Virginia.
F. Ty Edmondson has been our Chief Legal Officer since August 2020. Prior to joining Zai Lab, he served in various legal and compliance roles during his tenure at Biogen from June 2014 through August 2020. Most recently, Mr. Edmondson served as Senior Vice President, Chief Corporation Counsel and Assistant Secretary. Prior to that, he also served as the Chief Compliance Officer and Chief Commercial Counsel of Biogen. Prior to Biogen, Mr. Edmondson served as Vice President, Associate General Counsel and Corporate Secretary for Sepracor, Inc. as well as in various senior legal and compliance positions in Japan and China after Sepracor’s acquisition by Sumitomo Dainippon Pharma, Co., Ltd. Before Sumitomo, Mr. Edmondson served in various roles with life sciences companies, including Eisai, Inc., Boston Scientific and Bristol-Myers Squibb, with a focus on international and U.S. FDA work. Before his work in the life sciences industry, he was an associate with the admiralty law firm, Royston Rayzor in Houston, Texas.Mr. Edmondson is a graduate of Washington & Lee University and holds a J.D. from the Widener University School of Law.
Tao Fu has been our President & Chief Operating Officer since September 2018, and a member of our Board of Directors since 2017. Prior to joining Zai Lab, he worked at Portola Pharmaceuticals, where he served as Executive Vice President, Chief Commercial and Business Officer, responsible for commercial operations, marketing, sales and business development functions. Prior to joining Portola in June 2015, Tao was Vice President and Head of Mergers & Acquisitions and Alliance Management at Bristol-Myers Squibb (BMS). At BMS, he was responsible for the company's corporate development, alliance management and venture activities. Between 2003 and 2014, he held several leadership positions with increasing responsibilities at Janssen, the pharmaceuticals group of Johnson & Johnson, most recently as Vice President, Business Development, where he led global M&A activities. He also has experience in business development, commercial strategy and management consulting with McKinsey & Company and Becton Dickinson.
Tao holds an M.S. in biology from the University of Rochester and an M.B.A in finance and marketing from Vanderbilt University. He did his undergraduate studies in biology at Tsinghua University in Beijing, China and is a Chartered Financial Analyst (CFA).
Dr. Hei has been our Chief Medical Officer, Oncology since August 2018. He brings over 20 years' experience in clinical development in Oncology. Prior to joining Zai Lab, Dr. Hei was the Chief Medical Officer (CMO) at Qilu Pharmaceuticals responsible for the overall strategy and operations of clinical development programs in all therapeutic areas. Dr. Hei joined Qilu from the San Diego-based biotechnology company Ambrx, where he served as the CMO responsible for the clinical strategy and operations, focusing on antibody-drug conjugates (ADCs) and bispecific antibodies. Prior to Ambrx, Dr. Hei had worked at Amgen for approximately 10 years as the Executive Medical Director in oncology global development and medical affairs. In particular, he was the Global Development Leader for numerous oncology pipeline molecules and marketed products including small molecules such as Motesanib as well as biologics such as conatumumab and Vectibix. Additionally, during his tenure at Amgen, Dr. Hei spent three years in China as the Medical Head to build the clinical medical teams and establish product development and clinical operation capabilities for Amgen China. Before Amgen, Dr. Hei served as the US Medical Director for Roche, and Senior Global Brand Medical Director/Executive Director for Novartis Oncology where he led the development and execution of medical plans and expanded investigator-initiated clinical research. In addition, Dr. Hei supported regulatory filings and submissions at the FDA, PMDA (Japan), EMA, and the Chinese FDA (CFDA).
Dr. Hei holds a medical degree from Shihezi Medical College in China, and graduate degrees from the West China University of Medical Sciences (M.Sc) and the University of British Columbia in Canada (Ph.D.).
William Liang is our Chief Commercial Officer, President, Greater China, since June 2018. Prior to joining Zai Lab, William served as Vice President at AstraZeneca heading up the Oncology Business Unit in China. Under his leadership, AstraZeneca built a top performing oncology franchise in China by significantly outgrowing the market with many successful product launches, including setting a new benchmark for the successful market launch of Tagrisso®. During his tenure, Mr. Liang expanded his team from approximately 500 to 2,000 professionals and introduced a patient-centric business model to establish AstraZeneca’s oncology leadership position in China. Prior to AstraZeneca, he was Vice President of Oncology at Bristol-Myers Squibb in China, where he rebuilt the oncology sales team to achieve substantial sales growth. Previously, he spent over 13 years in senior commercial roles at Roche, where he began his career and ultimately achieved the position of China Business Unit Director of Oncology.
Mr. Liang holds a Medical Degree in Clinical Medicine from Fudan University and an Executive MBA degree from the China Europe International Business School.
Harald Reinhart, M.D., has been our Chief Medical Officer, Autoimmune & Infectious Disease since 2017. He is currently Adjunct Clinical Professor of infectious diseases at Yale School of Medicine. Prior to joining Zai Lab, Dr. Reinhart worked at Shionogi US as Head of Clinical Development and Medical Affairs, directing a broad portfolio of antibiotics, diabetes, allergy and pain medications. He guided several compounds through regulatory meetings, and obtained approval for ospemifene. Between 2003 and 2011, he held senior roles at Novartis where he oversaw successful filings of SNDAs and NDAs for Coartem, Famvir, Sebivo, and Cubicin, managed clinical development groups for infectious disease, immunity, transplantation, and renal disease. He supervised the transitioning of research projects into clinical developmenmt. In the years before, he was International Clinical Project Manager in charge of ciprofloxacin and acarbose at Bayer Corp., with several successful SNDAs and approvals.
Dr. Reinhart holds a medical degree from the University of Würzburg in Germany where he trained in anesthesiology. He completed his medical specialty training in the United States with board-certifications in internal medicine and infectious diseases.
Jonathan Wang is our Senior Vice President, Head of Business Development since 2014. Prior to joining Zai Lab, Mr. Wang was an investment professional at OrbiMed, where he was responsible for China healthcare investment and portfolio management. From 2005 to 2011, Mr. Wang worked as a consultant at the Boston Consulting Group in China, where he specialized in pharmaceutical and healthcare engagements, assisting multinational and local companies with their China strategy. Previously, Mr. Wang also gained financial transactional experience at Goldman Sachs Investment Banking.
Mr. Wang holds a Master of Business Administration in healthcare management from Wharton Business School.
Ning Xu, M.D., is our Executive Vice President, Clinical Operations. Prior to joining Zai Lab in 2014, he served as vice president, head of clinical development service at Covance China. Before joining Covance, Dr. Xu served as a senior medical and regulatory affairs executive at Johnson & Johnson and GlaxoSmithKline.
Dr. Xu holds a medical degree from Peking Union Medical College and a Master of Business Administration from the University of Illinois at Chicago. Dr. Xu also completed a postdoctoral fellowship at the Medical School, University of lllinois at Chicago. Between 2011 and 2015, he was the chairman of the Advisory Council of DIA China and a director of DIA Global. In 2020, he was selected as a member of the DIA Fellows Class.
James Yan, Ph.D., has been our Chief Operating Officer, R&D since April 2020. Prior to this role, he was the Executive Vice President and Head of Pre-Clinical Development and Program & Portfolio Management. Prior to joining Zai Lab, Dr. Yan was the head of the Covance early development Shanghai site, where he was responsible for all aspects of the business. Between 2009 and 2012, Dr. Yan served as the head of drug safety evaluation and program management of Hutchison Medi-Pharma. Prior to Hutchison Medi-Pharma, Dr. Yan had significant experience at Pfizer in the United States. Over the course of his career, Dr. Yan was involved in many IND and NDA filings for multiple drug candidates and gained substantial experience working with regulatory agencies in several countries.
Dr. Yan holds a Ph.D. from Peking Union Medical University and completed post-doctoral training at the University of Chicago’s Ben-May Institute for Cancer Research. He is a diplomat of the American Board of Toxicology (DABT), a council member of the China Society of Toxicology and a member of the Drug Toxicity and Drug Safety Evaluation Committee, a member of Pharmaceutical Toxicology Committee of China Pharmacology Society and vice chairman of Drug R&D Committee of China Pharmaceutical Innovation and Research Association (PhIRDA).